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Abstract
Background: Titanium dioxide (TiO2) nanoparticles are among the most manufactured nanomaterials in the
industry, and are used in food products, toothpastes, cosmetics and paints. Pregnant women as well as their
conceptuses may be exposed to TiO2 nanoparticles; however, the potential effects of these nanoparticles during
pregnancy are controversial, and their internal distribution has not been investigated. Therefore, in this study, we
investigated the potential effects of oral exposure to TiO2 nanoparticles and their distribution during pregnancy.
TiO2 nanoparticles were orally administered to pregnant Sprague-Dawley rats (12 females per group) from gestation
days (GDs) 6 to 19 at dosage levels of 0, 100, 300 and 1000 mg/kg/day, and then cesarean sections were conducted
on GD 20.
Results: In the maternal and embryo-fetal examinations, there were no marked toxicities in terms of general clinical
signs, body weight, food consumption, organ weights, macroscopic findings, cesarean section parameters and fetal
morphological examinations. In the distribution analysis, titanium contents were increased in the maternal liver,
maternal brain and placenta after exposure to high doses of TiO2 nanoparticles.
Conclusion: Oral exposure to TiO2 during pregnancy increased the titanium concentrations in the maternal liver,
maternal brain and placenta, but these levels did not induce marked toxicities in maternal animals or affect
embryo-fetal development. These results could be used to evaluate the human risk assessment of TiO2 nanoparticle
oral exposure during pregnancy, and additional comprehensive toxicity studies are deemed necessary considering
the possibility of complex exposure scenarios and the various sizes of TiO2 nanoparticles.
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Introduction
Nanotechnology is a rapidly growing field in recent de-
cades and is widely applied in various areas of industry
[1]. The use of nanotechnology extends to cosmetics,
fabrics and clothing, personal care items, cleaning solu-
tions, sporting equipment and electronics as well as toys
for children [2, 3]. Nanomaterials comprise natural, inci-
dental or manufactured material-containing particles
with one or more external dimensions in the size range
of 1 nm – 100 nm [4]. The size-dependent properties of
nanomaterials increase the surface-to-interaction, the pos-
sibility of improper interactions with intracellular compo-
nents and unusual electronic properties, such as electron
donation or acceptance [5]. These characteristic properties
raise concerns regarding the potential health risk to
humans and livestock, as well as the environment [6, 7].
Titanium dioxide (TiO2) nanoparticles are also widely
used nanomaterials and are among the top five nano-
materials used in consumer products [8]. TiO2 nano-
particles are used in paints, coatings, plastics, papers,
inks, medicines, pharmaceuticals, food products, cos-
metics and toothpastes [9–11]. The constant use of
TiO2 nanoparticle-containing products increases the
possibility of chronic exposure and accumulation in the
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internal organs of humans. In particular, oral and re-
spiratory exposures are considered the most prevalent
exposure routes to humans [12]. Oral exposure is an
important route for absorption because water, liquid
beverages and drug carriers may contain TiO2 nanopar-
ticles [13]. When TiO2 nanoparticles (25, 80, and 155
nm; 5 g/kg; single oral dose in mice) enter the circula-
tory system via oral exposure, they are retained in the
internal organs [14].
Several toxicity studies with TiO2 nanoparticles have
been recently conducted; however, there is little toxico-
logical information on TiO2 nanoparticle exposure dur-
ing pregnancy. Shimizu et al [15] reported that
subcutaneous exposure to TiO2 nanoparticles (2570 nm;
100 μl suspended at 1 μg/μl) during gestation (gestation
days [GDs] 6, 9, 12 and 15) in ICR mice induced
changes in gene expression related to brain develop-
ment, cell death, response to oxidative stress, and mito-
chondria in the brain during the prenatal period. Takeda
et al. [16] reported that subcutaneous exposure of ICR
mice to TiO2 nanoparticles (25 and 70 nm; 16 mg/kg)
during gestation (GDs 3, 7, 10 and 14) induced postnatal
reproductive toxicities in male offspring, including dis-
rupted seminiferous tubules and tubule lumens with few
mature sperm, decreased sperm production and epididy-
mis sperm motility. In addition, TiO2 nanoparticles were
detected in cells of the olfactory bulb and cerebral cortex
in these postnatal animals. These previous studies indi-
cated that TiO2 nanoparticle exposure during pregnancy
is able to induce toxic effects. However, the opposite re-
sult was also reported: oral exposure of six types of TiO2
particles, including pigment grade and nanoscale (42, 43,
47, 153, 195 and 213 nm; 100, 300, and 1000mg/kg;
daily, beginning on GDs 6 through 20 in rats), did not
induce maternal and embryo-fetal developmental toxic-
ities [17].
The objective of this study was to confirm the mater-
nal and embryo-fetal toxicities of orally exposed TiO2
nanoparticles during pregnancy. In addition, we also an-
alyzed the internal concentration of titanium in maternal
and fetal tissues. The results of this study will contribute
to elucidating the potential effects of TiO2 nanoparticles
on humans and support the accurate risk assessment of
these nanoparticles at different sizes and under complex
exposure scenarios.
Materials and methods
TiO2 nanoparticles and physicochemical characterization
TiO2 nanoparticles were obtained from Evonik Indus-
tries (Germany) as a fine white powder with a hydro-
philic characteristic caused by hydroxyl groups on the
surface. The nanoparticles consisted of aggregated pri-
mary particles; the mean diameter of the primary par-
ticle was approximately 21 nm, and the weight ratio of
anatase/rutile was approximately 80/20 according to the
manufacturer’s information.
Physicochemical characterization of TiO2 nanoparti-
cles was confirmed with an additional analytical method.
The primary particle size and morphology were analyzed
by a transmission electron microscope (JEM-2100F,
JEOL, Japan) operating at 200 kV. TiO2 NPs for trans-
mission electron microscope (TEM) analysis were de-
posited on carbon-coated nickel mesh grids and were
air-dried overnight before analysis. The purity was also
analyzed with energy-dispersive X-ray (EDX) analysis on
the same TEM images (JEM-2100F TEM equipped with
an X-MaxN 150mm2 silicon drift detector, Oxford In-
struments, UK). The average primary particle size was
calculated by measuring at least 100 particles using an
image analyzer program (DigitalMicrograph, Gatan Inc.,
USA). The hydrodynamic diameter and zeta potential of
TiO2 nanoparticles in deionized water (10 mg/ml con-
centration) were analyzed by the dynamic light scatter-
ing (DLS) method (ELS-8000, Otsuka Electronics,
Japan).
Animals and experimental design
Nine-week-old specific pathogen free (SPF) female Spra-
gue-Dawley rats were obtained (Orient Bio Inc., Repub-
lic of Korea) and permitted a 5-days period of
acclimation to the animal room environment. Females
were selected for mating on the basis of adequate body
weight and freedom from clinical signs of disease or in-
juries during the acclimation period. Females were
mated by placement in the cage of a male that was
maintained only for mating without any treatment.
Sixty-four mating-proven female rats were selected for
this study. The day of sperm and/or vaginal plugs detec-
tion was designated as day 0 of gestation. Pregnancy was
determined by confirmation of implantation sites on the
uterus at the time of final sacrifice.
The animal room environment was automatically con-
trolled according to institutional criteria (target range:
temperature of 23 ± 3 °C, relative humidity of 30–70%,
approximately 12-h light cycle with 150–300 Lux, and
ventilation at 10–20 times/hour). A standard rodent pel-
let diet irradiated by gamma-ray (PMI Nutrition Inter-
national, USA) was provided to the animals ad libitum.
Titanium was not detected in the rodent pellet diet ac-
cording to the chemical composition results from the
supplier. The animals had ad libitum access to filtered,
ultraviolet light-irradiated municipal tap water at all
times. Aspen animal bedding material (Bio Lab, Republic
of Korea) was sterilized and then provided to the ani-
mals in each cage. There were no known contaminants
in the food, water and bedding at levels that would be
expected to interfere with the results of the study.
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TiO2 nanoparticles were suspended in deionized water
for administration via the gastrointestinal route. To ob-
tain a homogenized suspension, the dosing formulation
was continuously stirred with a magnetic stirrer during
the dosing procedure. TiO2 nanoparticles were adminis-
tered by oral gavage to mated females to evaluate the
potential maternal and embryo-fetal development tox-
icity of TiO2 nanoparticles. This study design refers to
the OECD Guideline 414 (Prenatal Developmental Tox-
icity Study) [18] and was carried out in a good labora-
tory practice (GLP) facility but was not conducted
within the scope of GLP regulations. In addition, we also
analyzed the internal distribution of titanium in mater-
nal and fetal tissues after repeated oral exposure during
pregnancy. Twelve females per group in the toxicology
group (total 48 females) and 4 females per group in the
tissue distribution group (total 16 females) were used in
this study. TiO2 nanoparticles were administered daily
by oral gavage from GDs 6 to 19 at dose levels of 0, 100,
300 and 1000mg/kg with a dose volume of 10 mL/kg.
All procedures with animals were in compliance with
the Animal Protection Act of Korea and the Guide for
the Care and Use of Laboratory Animals published by
the Institute for Laboratory Animal Research (ILAR).
The Korea Institute of Toxicology (KIT) received full ac-
creditation from the Association for Assessment and Ac-
creditation of Laboratory Animal Care International
(AAALAC International) in 1998, which has been
renewed regularly. This study was reviewed and assessed
by the Institutional Animal Care and Use Committee
(IACUC) of KIT.
In-life maternal examinations
A mortality observation was conducted twice daily (once
at the start of the animal room procedure and once at
the end of the animal room procedure). Observation of
general clinical signs, including general appearance and
behavioral changes, were conducted twice a day during
the treatment period (before and after dosing) and once
a day during the nontreatment period. During preg-
nancy, maternal animals were especially monitored for
signs of abortion or premature delivery. Body weights
and food consumption were measured individually on
GDs 0, 6, 9, 12, 15, 17 and 20.
Cesarean section and fetal morphological examinations
On GD 20, all toxicology group females were euthanized
using CO2 gas for macroscopic observation and cesarean
section. All females were examined carefully for external,
abdominal, thoracic and cranial cavity abnormalities.
Special attention was paid to the organs of the repro-
ductive system. Gravid uteri were retrieved and then
weighed to calculate the corrected terminal weight (body
weight on GD 20 minus gravid uterine weight) and the
net body weight change (corrected terminal weight
minus body weight on GD 6). The corpora lutea, im-
plantation sites, live/dead fetuses and resorptions (early
or late) were counted or measured, and then calculated
pre-implantation loss, post-implantation loss and fetal
death. Each live fetus was weighed and sexed. In
addition, each placenta was weighed and examined
macroscopically.
Fetal morphological examinations, including external,
visceral and skeletal examinations, were conducted. Fe-
tuses were numbered from the left uterine horn to the
right uterine horn. Alternate fetuses were selected for ei-
ther skeletal or visceral examination (odd numbers: skel-
etal examination, even numbers: visceral examination).
Live fetuses retrieved from gravid uteri were examined
immediately to evaluate external abnormalities. For fetal
visceral examinations, fetuses were fixed with Bouin’s so-
lution, and then modified Wilson’s method [19] for the
head, Nishimura’s method [20] for the thorax and Stap-
les’s method [21] for the abdomen were used. For skel-
etal examinations, fetuses were fixed with 70% ethanol,
and then Dawson’s method [22] was used after staining
with alizarin red. Fetal morphological abnormalities were
classified as malformation or variations according to the
severity of findings. In addition, we used the terminology
suggested in an internationally developed glossary of
terms for structural developmental abnormalities in
common laboratory mammals [23].
Tissue collection and preprocessing
On GD 20, all tissue-distribution group females were eu-
thanized using CO2 gas to conduct the tissue collection.
Maternal tissue collection (approximately 200 mg each),
including liver (middle lobe), brain, and blood, was con-
ducted. Fetal tissue collection (approximately 200 mg
each), including liver, brain, blood and placenta, was
conducted. At least 3 fetuses from a litter were used for
fetal tissue collection, and collected samples were pooled
by a litter. All collected samples were weighed to quanti-
tatively calculate the tissue distribution and then main-
tained in frozen condition (approximately − 80 °C) until
titanium content analysis.
For the evaluation of tissue levels of titanium, the sam-
ples were digested with a tri-acid mixture. The tri-acid
mixture was prepared with concentrated hydrofluoric
acid (HF, 49%, J.T. Baker, USA), nitric acid (HNO3, 60%,
Matsunoen Chemical LTD, Japan), and hydrogen perox-
ide (H2O2, 30%, J.T. Baker, USA) mixed in a ratio of 1:4:
1, and 12mL of this mixture was added to each Teflon
reaction vessel containing a sample [24–26]. Thereafter,
the samples with mixed acid were heated on a graphite
digestion system (ODLAB, OD-98-002P, Republic of
Korea) for 1 h, and digested residues were made up to
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10mL with 1% (v/v) HNO3 (pH = 1–2). The final sam-
ples were stored at − 4 °C before analysis.
Titanium distribution analysis
Inductively coupled plasma mass spectrometry (ICP–
MS, ELAN DRC II, Canada) was used to measure titan-
ium concentrations in the collected samples. Instrumen-
tal operating conditions were as follows: 1500W of
radiofrequency (RF) power, 0.9 L/min of nebulizer gas
flow rate, and 1.5 L/min of auxiliary gas flow rate. Cali-
bration standards of 1, 5, 10, 20, and 40 μg/L for titan-
ium (1000mg/L, Merck, Germany) were used, and
coefficients of determination (R2) for titanium were
higher than 0.999. Blank samples, which consisted of so-
lutions without the presence of tissue, were used for the
assessment of contamination during the experiments.
The digestion method was applied to blank samples in
order to measure the likely amounts of titanium con-
tamination. Teflon tubes, 15 mL polypropylene tubes,
and chemicals were all potential sources of titanium
contamination [26]. For instrumental detection limits
(IDLs), 1 mL of the lowest level of calibration standard
(1 μg/L) was injected into the ICP–MS seven times (n =
7), and a standard deviation of analytical data was multi-
plied by a Student’s t value of 3.14. For method detection
limits (MDLs) and the limit of quantification (LOQ), 2
mL of 5 μg/L standard was spiked into the seven blank
samples, and standard deviations were multiplied by
3.14 and 10, respectively. The final volume in each blank
sample was 10mL. ICP–MS was sensitive enough to
quantify all of our samples, and there was no need to
improve the IDL of 0.038 μg/L. The MDLs and LOQ for
the collected samples were determined to be 0.0001 mg/
kg and 0.0002 mg/kg, respectively. The values presented
high sensitivity and a satisfactory recovery rate (96.5 ±
2.4%). Maternal samples for non-pregnant subjects were
excluded from the concentration analysis, and two sam-
ples (one fetal blood at vehicle control and one maternal
liver at 100mg/kg) were excluded from the concentra-
tion analysis because they were considered to be
contaminated.
Statistical analysis
Statistical analyses for comparisons of the various dose
groups with the vehicle control group were conducted
using the Pristima System (Version 7.2, Xybion Medical
System Co., USA) or SAS/STAT (Version 9.4, SAS Insti-
tute Inc., USA). Litter data were statistically evaluated
using the litter as a statistical unit. Multiple comparison
tests for different dose groups were conducted. Continu-
ous data were examined for variance in homogeneity
using Bartlett’s Test. Homogeneous data were analyzed
using analysis of variance (ANOVA), and the signifi-
cance of intergroup differences was analyzed using
Dunnett’s test. Heterogeneous data were analyzed using
the Kruskal-Wallis test, and the significance of inter-
group differences between the control and treated
groups was assessed using Dunn’s rank sum test. One-
way analysis of covariance (ANCOVA) was used to
analyze fetal and placental weight data. The litter size
was used as the covariate.
Results
Physicochemical characterization of TiO2 nanoparticles
The physicochemical characterization of TiO2 nanopar-
ticles, including analyses of primary shape, primary size,
purity, hydrodynamic size and zeta potential, is summa-
rized in Table 1. The majority of the TiO2 nanoparticles
had spherical and anatase crystal shapes with a purity of
100%. The mean primary size of the TiO2 nanoparticles
was 17.8 ± 5.46 nm. The hydrodynamic size of the TiO2
nanoparticles was 341.5 nm, which indicates that TiO2
nanoparticles were prone to aggregation and formed a
larger size in the vehicle. The zeta potential of the TiO2
nanoparticles in the vehicle was 35.16 mV.
Mortality and general clinical sign observation
All female rats survived through the end of the study,
and no abnormal general clinical signs were observed in
any group throughout the study.
Body weights and food consumption
No test item-related changes in body weight and body
weight gain were observed during the study period
(Table 2). For food consumption, a statistically signifi-
cant decrease during the study period (92% of control)
at 1000mg/kg was considered test item-related (Table 3).
However, this decrease did not have toxicological rele-
vance since it was minimal and there was no correlated
decreased body weight or body weight gain during the
study period.
Organ weights and gravid uterine weight
There was no test item-related change in absolute and
relative organ weights in this study (Table 4). In
addition, there was no test item-related change in gravid
uterine weight, corrected terminal body weight (body
weight on GD 20 minus gravid uterine weight) and net
body weight change (corrected terminal body weight
minus body weight on GD 6) in this study (Table 5).
Cesarean section and fetal morphological examinations
There was no test item-related change in cesarean
section parameters, including corpora lutea, implant-
ation, resorptions (early and late), dead and live
fetuses, sex ratio, pre-implantation loss, post-implant-
ation loss, fetal weight, placental weight and placental
macroscopic observation (Table 6). In addition, there
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was no test item-related change in the fetal external
and visceral examinations (Table 7). In the skeletal
examination, an increased ossification site of metatar-
sals in both hindlimbs was only observed at 100 mg/
kg, but it was considered incidental since it did not
have a dose response and there were no changes in
other related parameters (Table 8).
TiO2 nanoparticle distribution in tissues
The titanium contents were analyzed in maternal tissues
(liver, brain and blood) and fetal tissues (liver, brain,
blood and placenta) after the oral exposure of TiO2
nanoparticles during pregnancy (Fig. 1). Titanium con-
centrations in maternal liver, maternal brain and pla-
centa at 1000mg/kg were elevated compared to the
Table 2 Body weights and body weight gain of TiO2 nanoparticles exposed pregnant females during the pregnancy
TiO2 nanoparticles (mg/kg)
0 100 300 1000
Pregnant Females (N) 12 12 12 12
Body Weight (g)
Gestation day 0 235.4 ± 8.88a 235.4 ± 8.93 235.6 ± 9.19 235.5 ± 9.70
Gestation day 6 275.5 ± 12.08 277.4 ± 11.41 274.5 ± 10.31 276.8 ± 13.64
Gestation day 9 288.1 ± 13.17 288.4 ± 12.59 286.6 ± 9.74 286.7 ± 14.86
Gestation day 12 307.5 ± 14.00 307.3 ± 13.20 307.6 ± 10.38 306.3 ± 18.14
Gestation day 15 323.5 ± 15.19 325.8 ± 15.92 326.7 ± 12.20 321.0 ± 19.40
Gestation day 17 342.8 ± 17.30 346.9 ± 16.35 349.2 ± 11.13 341.4 ± 18.53
Gestation day 20 389.3 ± 26.47 399.1 ± 22.46 400.1 ± 14.68 388.7 ± 21.15
Body Weight Gain (g)
Gestation day 6–20 (treatment period) 113.8 ± 16.81 121.7 ± 15.08 125.6 ± 9.16 111.9 ± 10.30
aValues are presented as mean ± S.D
Table 1 Physicochemical characterization of titanium dioxide nanoparticles
Physicochemical TiO2 nanoparticles
Primary Shape (TEM Image)
Primary Size 17.8 ± 5.46 nm
Purity 100%
Hydrodynamic Size 341.5 nm
Zeta Potential 35.16 mV
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concentration in control animals. In addition, at 300 mg/
kg, titanium concentrations in the maternal brain and
placenta were also slightly elevated. Moreover, there was
no titanium concentration change in the maternal blood,
fetal liver, fetal brain or fetal blood.
Discussion and conclusion
Oral exposure to TiO2 nanoparticles is one of the most
prevalent exposure scenarios because humans are
frequently exposed to TiO2 nanoparticles contained in
food products, liquid beverages and drugs [27, 28]. In
this study, we evaluated the potential effects of oral ex-
posure to TiO2 nanoparticles during pregnancy and their
distribution in maternal organs as well as fetuses. TiO2
nanoparticles were administered by oral gavage to preg-
nant Sprague-Dawley rats at doses of 0, 100, 300 and
1000 mg/kg. In-life and terminal experimental end-
points, including general clinical signs, body weight
Table 4 Absolute and relative organ weights of TiO2 nanoparticles exposed pregnant females
TiO2 nanoparticles (mg/kg)
0 100 300 1000
Pregnant Females (N) 12 12 12 12
Adrenal glands (g) 0.08 ± 0.010a 0.07 ± 0.010 0.07 ± 0.010 0.07 ± 0.009
Organ to terminal body weight ratio (%) 0.02 ± 0.003 0.02 ± 0.003 0.02 ± 0.003 0.02 ± 0.002
Brain (g) 1.86 ± 0.080 1.87 ± 0.089 1.83 ± 0.064 1.90 ± 0.045
Organ to terminal body weight ratio (%) 0.49 ± 0.047 0.49 ± 0.037 0.47 ± 0.021 0.50 ± 0.024
Heart (g) 1.09 ± 0.106 1.10 ± 0.087 1.12 ± 0.066 1.10 ± 0.103
Organ to terminal body weight ratio (%) 0.29 ± 0.028 0.28 ± 0.026 0.29 ± 0.018 0.29 ± 0.026
Kidneys (g) 2.05 ± 0.211 2.03 ± 0.160 2.06 ± 0.189 2.06 ± 0.192
Organ to terminal body weight ratio (%) 0.54 ± 0.049 0.52 ± 0.034 0.53 ± 0.047 0.55 ± 0.050
Liver (g) 14.19 ± 1.000 14.48 ± 1.039 15.16 ± 1.186 14.70 ± 0.823
Organ to terminal body weight ratio (%) 3.75 ± 0.229 3.75 ± 0.185 3.89 ± 0.237 3.88 ± 0.138
Pituitary gland (g) 0.01 ± 0.002 0.01 ± 0.003 0.01 ± 0.002 0.01 ± 0.002
Organ to terminal body weight ratio (%) 0.004 ± 0.0006 0.004 ± 0.0006 0.004 ± 0.0005 0.004 ± 0.0005
Spleen (g) 0.70 ± 0.116 0.69 ± 0.073 0.73 ± 0.115 0.71 ± 0.077
Organ to terminal body weight ratio (%) 0.19 ± 0.028 0.18 ± 0.018 0.19 ± 0.028 0.19 ± 0.019
Lung 1.35 ± 0.105 1.33 ± 0.112 1.35 ± 0.122 1.28 ± 0.107
Organ to terminal body weight ratio (%) 0.36 ± 0.032 0.35 ± 0.034 0.35 ± 0.030 0.34 ± 0.021
Right ovary (g) 0.06 ± 0.012 0.07 ± 0.01 0.06 ± 0.011 0.06 ± 0.011
Organ to terminal body weight ratio (%) 0.02 ± 0.003 0.02 ± 0.003 0.02 ± 0.003 0.02 ± 0.003
Left ovary (g) 0.06 ± 0.009 0.06 ± 0.011 0.06 ± 0.014 0.06 ± 0.012
Organ to terminal body weight ratio (%) 0.02 ± 0.002 0.01 ± 0.003 0.02 ± 0.004 0.02 ± 0.003
Thymus (g) 0.40 ± 0.084 0.37 ± 0.076 0.43 ± 0.066 0.37 ± 0.080
Organ to terminal body weight ratio (%) 0.11 ± 0.023 0.10 ± 0.019 0.11 ± 0.0175 0.10 ± 0.023
aValues are presented as mean ± S.D
Table 3 Food consumption of TiO2 nanoparticles exposed pregnant females during the pregnancy
TiO2 nanoparticles (mg/kg)
0 100 300 1000
Pregnant Females (N) 12 12 12 12
Food Consumption (g)
Gestation day 0–6 24.3 ± 2.70a) 23.3 ± 1.95 24.0 ± 2.00 22.9 ± 1.55
Gestation day 6–9 26.0 ± 2.60 25.4 ± 1.97 25.7 ± 1.44 23.7 ± 1.77*
Gestation day 9–12 26.6 ± 2.84 24.8 ± 1.50 26.0 ± 1.35 23.5 ± 2.70
Gestation day 12–15 26.0 ± 2.19 25.6 ± 2.22 26.2 ± 1.70 24.1 ± 2.38
Gestation day 15–17 27.1 ± 1.92 26.9 ± 2.37 28.0 ± 2.12 25.6 ± 2.52
Gestation day 17–20 27.7 ± 2.43 27.1 ± 2.02 28.5 ± 2.05 26.2 ± 2.10
Gestation day 6–20 (treatment period) 26.7 ± 2.15 25.9 ± 1.73 26.8 ± 1.39 24.5 ± 2.04**
aValues are presented as mean ± S.D
**Significant difference at p < 0.01 level compared with the control group
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changes, food consumption, macroscopic findings, organ
weights, cesarean section parameters and fetal morph-
ology, including external, visceral, and skeletal aspects,
were examined. There were no TiO2 nanoparticle-re-
lated toxicological findings related to maternal and em-
bryo-fetal development toxicity parameters during the
study. In addition, increased titanium concentrations in
the maternal liver, maternal brain and placenta were ob-
served after high dose oral exposure during pregnancy.
The molecular mechanism of TiO2 nanoparticle-in-
duced toxicity is regarded as the induction of inflamma-
tion and generation of reactive oxygen species (ROS).
The accumulation of TiO2 nanoparticles induces chronic
inflammation, which leads to the formation of ROS and
cell proliferation [29]. Previous studies have demon-
strated that TiO2 nanoparticle exposure induces the
expression of inflammatory cytokines, including IL-1a,
IL-1b, IL-2, IL-4, IL-6 and IL-18 [30–32]. In addition,
the role of free radicals in DNA damage [27, 33], ROS-
induced activation of p53-mediated DNA damage [28]
and cell-derived oxidants involved in the induction of
mutagenesis [34] after TiO2 nanoparticle exposure were
investigated. Although the exact pathophysiological
mechanism is not clear, these multifactorial events re-
lated to the induction of inflammation leading to the
production of ROS would be the major cause in TiO2
nanoparticle-induced toxicity.
Experimental animal studies were also conducted to
evaluate the potential effects of TiO2 nanoparticle ex-
posure. An acute oral toxicity study in mice (25, 80 and
155 nm, 5000mg/kg) reported no obvious acute toxicity,
but hepatic and renal injury was observed in the
Table 6 Caesarean section results of TiO2 nanoparticles exposed pregnant females during the pregnancy
TiO2 nanoparticles (mg/kg)
0 100 300 1000
Pregnant Females (N) 12 12 12 12
Corpora lutea (N) 14.1 ± 1.83a 14.6 ± 1.98 13.9 ± 1.31 14.1 ± 1.56
Implantation (N) 12.8 ± 3.81 14.4 ± 2.19 13.6 ± 1.38 13.2 ± 2.55
Early resorptions (N) 0.4 ± 0.67 0.2 ± 0.58 0.4 ± 0.67 0.4 ± 0.67
Late resorptions (N) 0.0 ± 0.00 0.2 ± 0.39 0.0 ± 0.00 0.0 ± 0.00
Dead fetuses (N) 0.0 ± 0.00 0.0 ± 0.00 0.0 ± 0.00 0.0 ± 0.00
Fetal death (resorptions + dead fetuses) 0.4 ± 0.67 0.3 ± 0.65 0.4 ± 0.67 0.4 ± 0.67
Live fetuses (N) 12.4 ± 3.55 14.1 ± 2.54 13.2 ± 1.34 12.8 ± 2.45
Sex ratio (%, male) 48.1 ± 18.87 63.0 ± 14.98 45.2 ± 7.01 53.7 ± 13.75
Pre-implantation loss (%)b 10.0 ± 22.13 1.4 ± 3.19 2.4 ± 3.57 7.0 ± 12.07
Post-implantation loss (%)c 2.7 ± 4.31 2.7 ± 5.98 3.0 ± 4.65 3.0 ± 5.18
Fetal weight (g) 4.24 ± 0.25 4.38 ± 0.30 4.23 ± 0.25 4.21 ± 0.25
Covariate adjusted means 4.22 4.40 4.23 4.20
Placental weight (g) 0.50 ± 0.06 0.49 ± 0.05 0.54 ± 0.14 0.49 ± 0.05
Covariate adjusted means 0.49 0.49 0.54 0.49
Placental macroscopic observation NAD NAD NAD NAD
NAD No Abnormalities Detected
aValues are presented as mean ± S.D
b[(No. of corpora lutea - No. of implantation) / No. of corpora lutea] × 100
c[(No. of implantation – No. of live fetuses) / No. of implantation] × 100
Table 5 Gravid uterine weight, corrected terminal weight and net body weight change of TiO2 nanoparticles exposed pregnant
females during the pregnancy
TiO2 nanoparticles (mg/kg)
0 100 300 1000
Pregnant Females (N) 12 12 12 12
Gravid uterine weight (g) 76.91 ± 21.44a 89.31 ± 15.33 81.92 ± 6.91 78.37 ± 13.18
Corrected terminal body weight (g)b 312.37 ± 16.87 309.78 ± 16.54 318.14 ± 12.20 310.37 ± 20.59
Net body weight change (g)c 36.88 ± 11.43 32.40 ± 8.89 43.69 ± 8.34 33.54 ± 10.82
aValues are presented as mean ± S.D
bBody weight on GD 20 – Gravid uterine weight
cCorrected terminal body weight – Body weight on GD 6
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histopathological examination [14]. A repeated oral tox-
icity study in rats (< 50 nm; 0.16, 0.4 and 1 g/kg for 14
days) revealed disturbances in metabolism and the gut
microflora environment caused by slight injury to the
liver and heart, as shown by urianalysis with nuclear
magnetic resonance (NMR) [35]. The results from
other experimental animal studies indicated that the
absorption of TiO2 nanoparticles is able to enter the
systemic circulation and induce organ injuries and
inflammation [12].
Reproductive and developmental toxicity potentials of
TiO2 nanoparticles were also reported in previous stud-
ies with zebrafish, mice and rats. In zebrafish studies,
TiO2 nanoparticles (20 nm; 5 mg/mL, 21 nm; 0.01, 10
and 1000 μg/mL and 240–280 nm in water; 0.1 μg/mL)
induced deformities in the cardiovascular system,
premature hatching and impaired reproduction [36–38].
In addition, TiO2 nanoparticle (25 nm; 0.1 μg/mL) ex-
posure alone did not induce toxicological effects but en-
hanced the metabolism of pentachlorophenol (PCP) and
caused oxidative damage and developmental toxicity
when co-exposed with PCP [39]. In mouse studies, sub-
cutaneous TiO2 nanoparticle exposure (2570 nm; 100 μl
suspended at 1 μg/μl; GDs 6, 9, 12. 15 and 25, 70 nm; 16
mg/kg; GDs 3, 7, 10 and 14) during pregnancy induced
genital and cranial nerve system damage in the offspring
and altered gene expression in the brain during the pre-
natal period [15, 16]. Intravenous TiO2 nanoparticle (35
nm; 0.8 mg/animal; GDs 16 and 17) exposure during
pregnancy induced smaller uteri and fetuses, and TiO2
nanoparticles were found in the placenta, fetal liver and
fetal brain [40]. In contrast, Warheit et al. [17] reported
that oral exposure to different sized TiO2 particles (42,
43, 47, 153, 195 and 213 nm; 100, 300, and 1000mg/kg;
daily beginning on GDs 6 through 20 in rats) did not in-
duce toxicities during pregnancy. Our study results con-
firmed that oral exposure to TiO2 nanoparticles during
pregnancy did not induce toxic effects in maternal ani-
mals or embryo-fetal development endpoints. This find-
ing is consistent with the study reported by Warheit et
al. [17], although the analyzed primary particle size of
the TiO2 nanoparticles was different from that in the
previous study.
This discrepancy in reproductive and developmental
results among previous studies is considered to be
caused by differences in exposure routes, animal species,
physicochemical properties of the nanoparticles, etc. In
fact, a gastrointestinal absorption study of silver nano-
particles reported that nanoparticles were aggregated
and changed their physical properties in the stomach,
and the degree of these changes was especially influ-
enced by the particle size of the nanoparticles [41]. This
study indicates that oral exposure to nanoparticles is
able to alleviate the toxicity by inducing the loss of char-
acteristic properties of nanoparticles before they enter
the systemic circulation when compared to directly sys-
temically exposed routes, such as intravenous and inhal-
ation routes. Quantitative biokinetics of TiO2
nanoparticle studies with oral and intravenous exposure
also proved that internal exposure was much higher with
intravenous than with oral exposure [42, 43]. These dif-
ferences in internal exposure might result in different in-
teractions and binding to blood proteins and
biomolecules with TiO2 nanoparticles, which will subse-
quently affect uptake in organs and tissues [44]. More-
over, species differences in metabolism and placentation
are considered to be important factors for birth defects
occurrence [45]. In fact, the birth defect levels for se-
lected developmental toxicants differ among animal spe-
cies and humans [46].
Table 7 Fetal external and visceral examination results of TiO2
nanoparticles exposed pregnant females during the pregnancy
TiO2 nanoparticles (mg/kg)
0 100 300 1000
Fetal External Examination
No. of litters examined 12 12 12 12
No. of fetuses examined 149 169 158 153
Malformation
No. of affected litters (%) 0 (0) 0 (0) 0 (0) 0 (0)
No. of affected fetuses (%) 0 (0) 0 (0) 0 (0) 0 (0)
Variation
No. of affected litters (%) 0 (0) 0 (0) 0 (0) 0 (0)
No. of affected fetuses (%) 0 (0) 0 (0) 0 (0) 0 (0)
Fetal Visceral Examination
No. of litters examined 12 12 12 12
No. of fetuses examined 72 81 75 74
Malformation
No. of affected litters (%) 0 (0) 0 (0) 0 (0) 0 (0)
No. of affected fetuses (%) 0 (0) 0 (0) 0 (0) 0 (0)
Variation
Thymus, Thymic cord
No. of affected litters (%) 7 (58) 7 (58) 7 (58) 5 (42)
No. of affected fetuses (%) 10 (14) 13 (16) 9 (12) 7 (11)
Kidneys, Dilated renal pelvis
No. of affected litters (%) 0 (0) 0 (0) 1 (8) 0 (0)
No. of affected fetuses (%) 0 (0) 0 (0) 2 (3) 0 (0)
Ureter, Convoluted ureter
No. of affected litters (%) 6 (50) 6 (50) 6 (50) 7 (58)
No. of affected fetuses (%) 11 (14) 9 (11) 14 (18) 10 (14)
Ureter, Dilated ureter
No. of affected litters (%) 7 (58) 5 (42) 4 (33) 7 (58)
No. of affected fetuses (%) 14 (18) 7 (8) 7 (9) 13 (17)
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The distribution analysis of maternal and fetal tissues
in this study showed that TiO2 nanoparticles were
retained in the maternal liver, maternal brain and pla-
centa at 1000 mg/kg after repeated oral exposure during
pregnancy. At 300 mg/kg, the TiO2 nanoparticle level
was also slightly elevated in the maternal brain and pla-
centa. However, it was indiscernible in the maternal
blood, fetal liver, fetal brain and fetal blood of all the
TiO2 nanoparticle-treated groups. Other studies have
also reported that TiO2 nanoparticles can be absorbed
into the systemic circulation and then distributed to in-
ternal organs. Single oral exposure of different sized
TiO2 particles (25, 80, and 155 nm; 5 g/kg) in mice
yielded retention of the particles in the liver, spleen, kid-
neys, brain and lung, but there was no detection of the
particles in blood. The distribution level in each tissue
varied depending on the TiO2 particle size [14]. Another
single oral exposure study of TiO2 nanoparticles (70 nm;
30–80 μg/kg) in rats reported that the TiO2 particles that
crossed the intestinal membrane accounted for less than
Table 8 Fetal skeletal examination results of TiO2 nanoparticles exposed pregnant females during the pregnancy
TiO2 nanoparticles (mg/kg)
0 100 300 1000
Fetal Skeletal Examination
No. of litters examined 12 12 12 12
No. of fetuses examined 77 88 83 79
Malformation
No. of affected litters (%) 0 (0) 0 (0) 0 (0) 0 (0)
No. of affected fetuses (%) 0 (0) 0 (0) 0 (0) 0 (0)
Variation
Ribs, Full thoracic supernumerary rib
No. of affected litters (%) 0 (0) 2 (17) 0 (0) 0 (0)
No. of affected fetuses (%) 0 (0) 2 (2) 0 (0) 0 (0)
Ribs, Short thoracic supernumerary rib
No. of affected litters (%) 2 (17) 4 (33) 3 (25) 2 (17)
No. of affected fetuses (%) 5 (6) 9 (10) 4 (5) 2 (2)
Skull, Large fontanelle
No. of affected litters (%) 3 (25) 2 (17) 0 (0) 0 (0)
No. of affected fetuses (%) 4 (5) 2 (2) 0 (0) 0 (0)
Thoracic centrum, Asymmetric ossification
No. of affected litters (%) 0 (0) 0 (0) 1 (8) 0 (0)
No. of affected fetuses (%) 0 (0) 0 (0) 1 (1) 0 (0)
Thoracic centrum, Bipartite ossification
No. of affected litters (%) 0 (0) 0 (0) 1 (8) 2 (17)
No. of affected fetuses (%) 0 (0) 0 (0) 2 (2) 3 (4)
Thoracic centrum, Dumbbell ossification
No. of affected litters (%) 2 (17) 1 (8) 0 (8) 2 (17)
No. of affected fetuses (%) 3 (3) 1 (1) 0 (0) 2 (3)
No. of ossification centers
Sternebra 5.9 ± 0.18a 5.9 ± 0.20 6.0 ± 0.08 5.8 ± 0.30
Metacarpals in both forelimbs 7.8 ± 0.38 8.0 ± 0.14 8.0 ± 0.12 7.9 ± 0.12
1st phalanges in both forelimbs 1.8 ± 1.39 2.7 ± 1.20 2.1 ± 1.12 2.6 ± 1.12
Metatarsals in both hindlimbs 8.0 ± 0.09 8.3 ± 0.38** 8.0 ± 0.09 8.0 ± 0.03
1st phalanges in both hindlimbs 0.2 ± 0.58 0.1 ± 0.20 0.0 ± 0.06 0.0 ± 0.00
Cervical vertebra 1.3 ± 1.29 1.3 ± 1.00 1.4 ± 1.23 0.9 ± 0.86
Sacral and caudal vertebra 8.5 ± 0.45 8.7 ± 0.49 8.5 ± 0.50 8.5 ± 0.34
aValues are presented as mean ± S.D
**Significant difference at p < 0.01 level compared with the control group
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0.6% of the applied dose; however, the TiO2 particles
were still distributed in the liver, lungs, kidneys, brain,
spleen, uterus and skeleton after 7 days of exposure [43].
A single intravenous administration study of TiO2 nano-
particles (20–30 nm; 5 mg/kg) in rats reported that the
nanoparticles were mainly retained in the liver as well as
the spleen and kidney but were not detected in the
blood, brain and lymph nodes [47]. A single intraperito-
neal administration of TiO2 nanoparticles (100 nm; 324–
2592 mg/kg) in mice yield retention in the spleen as well
as liver, kidney and lung, but nanoparticles were not de-
tected in the heart. The distribution level was changed
depending on the sample collection time after adminis-
tration [48]. These TiO2 nanoparticle distribution studies
concluded that the liver and kidney were the most com-
monly observed internal organs into which the particles
were distributed after they were absorbed into the sys-
temic circulation regardless of the administration route
and particle size. However, it was also concluded that
the TiO2 nanoparticle distribution can change depending
on the administration route, particle size and tissue sam-
pling time.
One intriguing distribution result in this study was the
relatively high level of TiO2 nanoparticles detected in
the brain. Distribution studies of TiO2 nanoparticles in
the brain have not been comprehensively conducted, but
several studies have suggested that TiO2 nanoparticles
can be deposited into the brain. Wang et al. [14] re-
ported that acute orally exposed TiO2 particles (25, 80
and 155 nm; 5 g/kg) in mice were deposited in the brain
and induced fatty degeneration in the hippocampus. Li
et al. [49] also reported that intratracheal instillation of
TiO2 particles (3 nm; 13.2 mg/kg, once a week for 4
weeks) in mice induced brain injury through oxidative
stress. Taken together, these previous studies indicate
that TiO2 nanoparticles are able to penetrate the blood-
brain barrier, and these results were consistent with our
study results.
No marked toxicities were observed in maternal ani-
mals and embryo-fetal development in this study design,
but this finding does not indicate that TiO2 nanoparti-
cles are completely safe during pregnancy. Generally,
two species (commonly rats and rabbits) are required in
this type of study to evaluate toxicity during pregnancy
[50]. In fact, rats and rabbits might be able to exhibit dif-
ferent teratogenic results during pregnancy [45]. More-
over, it is noteworthy that TiO2 nanoparticles (75 nm;
10, 50 and 200 mg/kg; daily oral for 30 days) are able to
induce liver edema (revealed by histopathological exam-
ination) and reductive stress (shown by biochemical as-
says) [51]. This result indicates that the toxicity of TiO2
nanoparticles can be detected by more sensitive and/or
different parameters. In this regard, additional repro-
ductive endpoints, including fertility, parturition, post-
natal development and hormone analysis, were not in-
vestigated, and these parameters will support the accur-
ate safety assessment of TiO2 nanoparticles. Considering
the possibility of complex TiO2 nanoparticles exposure
scenarios and their various particle sizes, it is necessary
to conduct additional studies to evaluate the potential
adverse effects of TiO2 nanoparticles.
In conclusion, we systemically investigated the mater-
nal and embryo-fetal effects of orally exposed TiO2
nanoparticles during pregnancy in rats. In addition, we
analyzed the titanium distribution during pregnancy
using maternal and fetal tissues. As a result, there were
Fig. 1 The contents of titanium in maternal and fetal tissues after orally exposed TiO2 nanoparticles during the pregnancy. Values are presented
as mean ± S.D. (n = 3 or 4). VC; vehicle control, T1–3; 100, 300, and 1000mg/kg TiO2 nanoparticles groups. **Significant difference at p < 0.01 level
compared with the control group
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no TiO2 nanoparticle-related toxicity findings in mater-
nal animals or with respect to embryo-fetal development
in this study design, and the titanium content was in-
creased in the maternal liver, maternal brain and pla-
centa with high-dose exposure to TiO2 nanoparticles.
The results of this study can be used to evaluate the hu-
man risk assessment of TiO2 nanoparticles during preg-
nancy, and additional toxicity studies are considered
necessary to elucidate the effects of TiO2 nanoparticles
under various exposure scenarios and at different par-
ticle sizes.
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